Solid Tumor Clinical Trial
Official title:
A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability and Pharmacokinetics of ISU104, a Human Monoclonal Antibody Targeting ErbB3 in Patients With Advanced Solid Tumors
Verified date | May 2021 |
Source | ISU Abxis Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A phase I, open-label, dose-finding study to assess the safety, tolerability and pharmacokinetics of ISU104, a human monoclonal antibody targeting erbB3 in patients with advanced solid tumors.
Status | Active, not recruiting |
Enrollment | 33 |
Est. completion date | December 31, 2021 |
Est. primary completion date | October 19, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: Common 1. Male or Female with = 19 years of age 2. Histologically or Cytologically confirmed a diagnosis of an advanced solid tumor that was refractory to standard treatment or for which no standard therapy existed, or patients declined any treatment options 3. Eastern Cooperative Oncology Group (ECOG) performance status = 2 4. Life Expectancy = 12 weeks 5. Adequate Hematological, Renal and Hepatic function 6. According to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1, the patient had at least one measurable lesion Exclusion Criteria: 1. Severe hypersensitivity or a history of any hypersensitivity to the similar drug class of IP 2. Patients underwent the major surgery or procedure, or had the medical history (as blow): - Major surgery requiring systemic anesthesia or respiratory assist device within 4 weeks prior to baseline [2 weeks in case of video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery)] - Severe cardiovascular disease within 24 weeks prior to baseline - Severe cerebrovascular disease within 24 weeks prior to baseline - Pulmonary thromboembolism, deep vein thrombosis (DVT) or other clinically and significantly severe lung disease within 24 weeks prior to baseline 3. Patients had the following concurrent diseases at baseline: - Hematologic malignancies including lymphoma - Clinically significant symptom or uncontrolled central nervous system (CNS) or brain metastases - Pleural effusion and ascites drainage - Uncontrolled hypertension (SBP/DBP > 160/100 mmHg) - Active hepatitis B or C virus - Human immunodeficiency virus (HIV) that is positive - Thromboembolic disease or bleeding diatheses - Interstitial lung disease (ILD) 4. Left ventricular ejection fraction (LVEF) value, when measured by echocardiogram, multiple gated acquisition (MUGA) scan or a standard procedure in the institution within 4 weeks prior to the study entry 5. Patients with the following medication history: - anti-ErbB3 targeted therapies - small-molecule tyrosine kinase inhibitors within 2 weeks prior to baseline - any anti-cancer therapy, including chemotherapy, radiotherapy, biologic therapy, retinoid therapy, or therapeutic/palliative radiotherapy for the treatment of advanced solid tumors within 4 weeks prior to baseline - Granulocyte-Colony Stimulating Factor (G-CSF), packed red cell or platelet transfusion within 2 weeks prior to the first injection of IP to correct the abnormal values of absolute neutrophil count (ANC) or platelet count 6. Pregnant woman, breastfeeding woman, or women of childbearing age and men with partners of childbearing age, unless they are willing to follow abstinence or use effective forms of contraception* from the study entry until at least 16 weeks after the EOT visit 7. Subjects receiving any other investigational products or medical devices within 4 weeks prior to screening 8. Principal investigator's opinion [Part 1 Dose-escalation cohort] 1. Patients with severe hypersensitivity or history of hypersensitivity to the similar drug class of the investigational product. 2. Patients receiving anti-cancer therapy, including chemotherapy, radiotherapy, biologic therapy, retinoid therapy, or therapeutic/palliative radiotherapy for treatment of advanced solid tumors within four weeks prior to baseline. [Part 2 dose-expansion cohort] 1. Patients with history of allergy or hypersensitivity to the investigational product (ISU104 or cetuximab) or any excipients of the investigational product or its similar derivatives. 2. Patients with primary malignant neoplasm, including head and neck cancer as specified in inclusion criteria of Part 2 dose-expansion cohort. However, an exception may be allowed for the following: - For respective malignancy, treatment-naïve or disease-free patients for at least three years (however, patients undergoing radical resection on papillary thyroid carcinoma may be eligible for this clinical trial, even though three years have not passed). - Total dissection of skin basal cell carcinoma/squamous cell carcinoma or at least one year had passed since successful treatment of cervical intraepithelial neoplasia. 3. Patients receiving anti-cancer therapy, including chemotherapy, radiotherapy, biologic therapy, retinoid therapy, therapeutic/palliative radiotherapy, or hormone therapy for treatment of advanced solid tumors within four weeks prior to baseline. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Kosin University Gospel Hospital | Busan | |
Korea, Republic of | Kyungpook National University Chilgok Hospital | Daegu | |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
ISU Abxis Co., Ltd. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the Maximum Tolerated Dose Dependent on Reports of Dose-limiting Toxicities | Determination of MTD is dependent upon number of cohorts and patients required | From date of first dose to 4 weeks after administration. | |
Secondary | Toxicity Evaluation | To determine the occurrence of Adverse Events (AEs) | through the study completion, an average of 1 year | |
Secondary | Determine Immunogenicity of ISU104 | To measure the level of Anti-Drug Antibody (ADA) and/or Neutralizing Antibody (NAb) of ISU104 | through the study completion, an average of 1 year | |
Secondary | Determine the Peak Plasma Concentration (Cmax) of ISU104 | To measure the Peak Plasma Concentration (Cmax) of ISU104 | up to 12 weeks | |
Secondary | Determine the Area Under the Curve (AUC) of ISU104 | To measure the Area under the plasma concentration versus time curve (AUC) of ISU104 | up to 12 weeks | |
Secondary | Explore Overall Response Rate (ORR) of ISU104 or ISU104+Cetuximab | To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as >30% decrease in tumor burden from baseline and a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline | up to progression, an average 6 months | |
Secondary | Explore Disease Control Rate (DCR) of ISU104 or ISU104+Cetuximab | To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as >30% decrease in tumor burden from baseline, a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline, and Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for Partial Response nor sufficient increase to qualify for Partial Response (defined as >20% decrease in tumor burden from baseline) | up to progression, an average 6 months | |
Secondary | Explore Progression-Free Survival (PFS) of ISU104 or ISU104+Cetuximab | To measure the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse | up to progression, an average 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |